All In Biotech

Drug Trial Radar · NCT05846867

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

An Open, Multicenter Phase Ib/II Clinical Study on the Efficacy and Safety of AK119 and AK112, Either in Combination or Not, With Chemotherapy, and AK112 Monotherapy in pMMR/MSS CRC

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

May 8, 2023

Primary completion

May 8, 2026

Study completion Aug 11, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC

Conditions

  • Colorectal Cancer

Interventions

  • AK119Drug

    AK119 IV every 2 weeks.intravenous infusion

  • AK112Drug

    AK112 IV every 2 weeks.intravenous infusion

  • OxaliplatinDrug

    Oxaliplatin: 85mg/m2, intravenous infusion

  • IrinotecanDrug

    Irinotecan 180mg/m2, intravenous infusion

  • Calcium folinateDrug

    Calcium folinate: 400mg/m2, intravenous infusion

  • FluorouracilDrug

    Fluorouracil 400mg/m2, intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 2 years
  2. Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
  3. recommended phaseII doseTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Affiliated to Harbin Medical University

    Harbin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.